We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 02, 2022

Distant Metastasis–Free Survival Outcomes Following Pembrolizumab vs Placebo as Adjuvant Therapy for Resected Stage IIB or IIC Melanoma

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial
Lancet Oncol 2022 Oct 17;[EPub Ahead of Print], GV Long, JJ Luke, MA Khattak, L de la Cruz Merino, M Del Vecchio, P Rutkowski, F Spagnolo, J Mackiewicz, V Chiarion-Sileni, JM Kirkwood, C Robert, JJ Grob, F de Galitiis, D Schadendorf, MS Carlino, P Mohr, R Dummer, JE Gershenwald, CH Yoon, XL Wu, M Fukunaga-Kalabis, C Krepler, AMM Eggermont, PA Ascierto

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading